CROI 2010: Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
- Details
- Category: Fibrosis & Cirrhosis
- Published on Friday, 26 February 2010 19:16
- Written by Liz Highleyman
Even moderate liver fibrosis (greater than stage F1) in HIV/HCV coinfected patients is associated with adverse clinical outcomes including liver cancer, liver failure, and death, investigators reported at the 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010) last week in San Francisco. However, effective HIV treatment producing long-term viral suppression and successful hepatitis C treatment leading to sustained virological response appeared to be protective.
More Articles...
- Liver Transplant Do Not Impair Immune Response in HIV/HCV Coinfected Patients
- Daily Coffee Consumption Is Linked to Less Severe Liver Fibrosis
- African Americans with Hepatitis C Have Worse Outcomes than White Patients after Liver Transplantation
- AASLD 2009: Study Looks at Factors Affecting Survival of HIV/HCV Coinfected Liver Transplant Recipients
- Rapid Liver Fibrosis Progression and Successful Treatment of Acute Infection Suggest Benefits of Routine HCV Screening for HIV Positive Men
Web Design and Development by